MWM
ATXS

MinichMacGregor Wealth Management’s Astria Therapeutics ATXS Stock Holding History

MinichMacGregor Wealth Management’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-100
Closed -$1.49K – 137
2022
Q4 		$1.49K Buy
+100
New +$1.03K ﹤0.01% 597

Other funds holding ATXS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

MinichMacGregor Wealth Management's ATXS Position: Q1 2023 in Review

MinichMacGregor Wealth Management sold out of Astria Therapeutics (ATXS) in Q1 2023, closing a stake of 100 shares — an estimated $1.49K sold.

MinichMacGregor Wealth Management first reported a position in ATXS in Q4 2022 and held it in 1 quarter. The position peaked at $1.49K in Q4 2022. 65 funds tracked by Wall St. Rank hold ATXS as of Q1 2023.

  • MinichMacGregor Wealth Management reported no remaining Astria Therapeutics position as of Q1 2023 after selling out during the quarter.
  • MinichMacGregor Wealth Management sold 100 Astria Therapeutics shares in Q1 2023, an estimated $1.49K.
  • MinichMacGregor Wealth Management first reported a position in Astria Therapeutics in Q4 2022 and held it in 1 quarter.
  • MinichMacGregor Wealth Management's Astria Therapeutics position peaked at $1.49K in Q4 2022.
  • 65 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2023.

Based on MinichMacGregor Wealth Management's 13F filing for Q1 2023, filed 19 Apr 2023.